- Home
- DBVT vs NECB Comparison
DBVT vs NECB Comparison
Compare DBVT & NECB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- NECB
- Stock Information
- Founded
- DBVT 2002
- NECB 1934
- Country
- DBVT France
- NECB United States
- Employees
- DBVT N/A
- NECB N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- NECB Savings Institutions
- Sector
- DBVT Health Care
- NECB Finance
- Exchange
- DBVT Nasdaq
- NECB Nasdaq
- Market Cap
- DBVT 273.6M
- NECB 281.2M
- IPO Year
- DBVT N/A
- NECB N/A
- Fundamental
- Price
- DBVT $9.66
- NECB $22.54
- Analyst Decision
- DBVT Buy
- NECB
- Analyst Count
- DBVT 4
- NECB 0
- Target Price
- DBVT $14.81
- NECB N/A
- AVG Volume (30 Days)
- DBVT 35.5K
- NECB 47.0K
- Earning Date
- DBVT 07-29-2025
- NECB 10-27-2025
- Dividend Yield
- DBVT N/A
- NECB 3.54%
- EPS Growth
- DBVT N/A
- NECB N/A
- EPS
- DBVT N/A
- NECB 3.29
- Revenue
- DBVT $3,800,000.00
- NECB $103,145,000.00
- Revenue This Year
- DBVT $1,743.46
- NECB $1.90
- Revenue Next Year
- DBVT $1,045.66
- NECB $6.93
- P/E Ratio
- DBVT N/A
- NECB $6.86
- Revenue Growth
- DBVT N/A
- NECB N/A
- 52 Week Low
- DBVT $2.21
- NECB $19.75
- 52 Week High
- DBVT $12.78
- NECB $31.72
- Technical
- Relative Strength Index (RSI)
- DBVT 49.63
- NECB 55.70
- Support Level
- DBVT $8.91
- NECB $22.00
- Resistance Level
- DBVT $10.34
- NECB $23.12
- Average True Range (ATR)
- DBVT 0.54
- NECB 0.71
- MACD
- DBVT -0.03
- NECB 0.20
- Stochastic Oscillator
- DBVT 52.61
- NECB 77.13
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.